Allspring Global Investments Holdings LLC cut its position in Inotiv, Inc. (NASDAQ:NOTV – Get Rating) by 3.8% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 130,525 shares of the company’s stock after selling 5,220 shares during the quarter. Allspring Global Investments Holdings LLC’s holdings in Inotiv were worth $2,199,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also bought and sold shares of NOTV. Quantbot Technologies LP lifted its stake in Inotiv by 30.8% in the 2nd quarter. Quantbot Technologies LP now owns 7,120 shares of the company’s stock worth $68,000 after purchasing an additional 1,678 shares in the last quarter. Amalgamated Bank purchased a new stake in Inotiv in the 1st quarter worth approximately $78,000. JPMorgan Chase & Co. lifted its stake in Inotiv by 13.7% in the 2nd quarter. JPMorgan Chase & Co. now owns 9,420 shares of the company’s stock worth $90,000 after purchasing an additional 1,136 shares in the last quarter. SG Americas Securities LLC purchased a new stake in Inotiv in the 2nd quarter worth approximately $112,000. Finally, Capital Impact Advisors LLC purchased a new stake in Inotiv in the 2nd quarter worth approximately $150,000. 52.04% of the stock is currently owned by hedge funds and other institutional investors.
Inotiv Price Performance
NOTV stock opened at $6.26 on Friday. The company has a debt-to-equity ratio of 0.54, a quick ratio of 1.15 and a current ratio of 1.60. Inotiv, Inc. has a 52 week low of $3.64 and a 52 week high of $42.63. The firm’s fifty day moving average is $6.53 and its 200 day moving average is $14.45. The firm has a market cap of $160.30 million, a P/E ratio of -0.45 and a beta of 2.43.
Wall Street Analyst Weigh In
Inotiv Company Profile
Inotiv, Inc operates as a pharmaceutical development company, which engages in the provision of drug discovery, development services, and analytical instruments. The firm operates through the following business segments: Research Services and Research Products. The Research Services segment provides screening and pharmacological testing, preclinical safety testing, formulation development, regulatory compliance, and quality control testing.
- Get a free copy of the StockNews.com research report on Inotiv (NOTV)
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving ’23 Growth
- Is Airbnb Setting Up To Rally 38%, As Analysts Are Forecasting?
- Does a Price Cut for Tesla Vehicles Mean the Same for TSLA Stock?
- Microsoft Layoffs Signal Layoffs for Other Tech Companies?
Receive News & Ratings for Inotiv Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inotiv and related companies with MarketBeat.com's FREE daily email newsletter.